Table 1.
Baseline characteristics and CYP2B6*6 and ABCB1 (c.4046A>G) genotypes of the study participants (n = 99).
Figure 1.
Individual predicted EFV concentrations (IPRED) versus observed concentrations, by CYP2B6*6 genotype (B66).
Figure 2.
The individually weighted residuals (WRES) are plotted vs. time.
The dashed line is the zero reference line while the solid line is a smooth nonparametric regression line. The plot demonstrates a good fit of all time point concentration data by the model.
Table 2.
Summary of significant factors in the covariate analysis; forward inclusion (α = 0.05) followed by backward elimination (α = 0.01).
Table 3.
Final model pharmacokinetic parameters.
Figure 3.
Distribution of estimated patient AUC values by CYP2B6 genotype.
CYP2B6*1/*1, CYP2B6 *1/*6, and CYP2B6 *6/*6. Dotted line = the mean AUC value in the product label.
Table 4.
Area under the curve (AUC) NONMEM estimate values for ABCB1 c. 4046A>G and or CYP2B6* 6 genotypes.
Table 5.
Simulation based AUC for 300
Table 6.
HIV viral loads at baseline and day 84 of treatment and AUC of study participants who failed to attain viral suppression to below detection by day 84.